Protocols

Current trials

NUCOG V

  • 3 vs 4 week GC as neoadjuvant treatment in muscle invasive bladder cancer.

NUCOG VI

  • Chemotherapy after immunotherapy in patients with locally advanced and metastatic urothelial cancer – an observational, non-interventional study.

 

Previous trials

VINGEM

  • Inclusion period: Q 3, 2013 – Q 1, 2018 
  • Sites: Karolinska University Hospital, Sweden, Akerhus University Hospital, Norway, Rigshospitalet, Denmark
  • Contact: Helle Pappot & Anders Ullén.

VINSOR

  • Inclusion period: Q3, 2011 – Q2, 2013
  • Sites: Karolinska University Hospital, Sweden, Rigshospitalet, Denmark, Aarhus University Hospital, Denmark.
  • Contact: Anders Ullén, Helle Pappot & Mads Agerbæk.

VINTREX

  • Inclusion period: Q3, 2014 – Q3, 2016
  • Sites: Rigshospitalet, Aarhus University Hospital, Odense University Hospital, Aalborg University Hospital, all Denmark.
  • Contact: Helle Pappot & Mads Agerbæk.




Responsible editor